Rates of Menstrual History-Taking and Counseling With Anticancer Treatments Are Low: People Who Menstruate Deserve Gender-Specific Cancer Care.

cancer care gender equality gender specific health care menstruation women of childbearing age

Journal

Journal of the National Comprehensive Cancer Network : JNCCN
ISSN: 1540-1413
Titre abrégé: J Natl Compr Canc Netw
Pays: United States
ID NLM: 101162515

Informations de publication

Date de publication:
04 2023
Historique:
received: 09 05 2022
accepted: 16 12 2022
medline: 6 4 2023
entrez: 4 4 2023
pubmed: 5 4 2023
Statut: ppublish

Résumé

Chemotherapy predisposes people who menstruate to abnormal uterine bleeding that can be life-threatening and may also damage ovaries, resulting in premature menopause. The purpose of this study was to explore the incidence of menstrual history documentation and counseling before, during, and after cancer treatment. The medical charts of 137 consecutive females (self-reported) aged 18 to 49 years receiving anticancer treatment at a major tertiary metropolitan hospital in Australia between 2017 and 2020 were reviewed. Data collected included primary diagnosis, stage of cancer, treatment(s) received, rates of remission or progression, documentation of involvement of a specialist gynecologist, reproductive history, menstrual disturbances, menstruation counseling or intervention offered, and diagnosis of early ovarian failure. Only 16.1% of patients had their menstrual history documented at the initial consult, and 49.6% had their menstrual history documented at a subsequent consult with their treating oncologist or hematologist. Most (82.4%) patients with a menstrual history documented experienced menstrual disturbance posttreatment, most commonly amenorrhea (48.0%), followed by menopause or menopause symptoms (20.6%), irregular menstrual bleeding (16.7%), menorrhagia (13.7%), dysmenorrhea (3.9%), and iron deficiency from bleeding (2.9%). Menopause/Menopausal symptoms and iron deficiency were more likely to be treated than other disturbances. Menstruation disturbance is a common side effect of cancer treatment. Menstrual care should be integral to cancer care for people who menstruate, and higher engagement could be achieved through education of medical and allied health staff, information technology systems automating prompts and referral pathways, regular audits to ensure compliance, better alliances between cancer and fertility specialists, and the creation of accessible patient information to promote awareness and facilitate discussion.

Sections du résumé

BACKGROUND
Chemotherapy predisposes people who menstruate to abnormal uterine bleeding that can be life-threatening and may also damage ovaries, resulting in premature menopause. The purpose of this study was to explore the incidence of menstrual history documentation and counseling before, during, and after cancer treatment.
PATIENTS AND METHODS
The medical charts of 137 consecutive females (self-reported) aged 18 to 49 years receiving anticancer treatment at a major tertiary metropolitan hospital in Australia between 2017 and 2020 were reviewed. Data collected included primary diagnosis, stage of cancer, treatment(s) received, rates of remission or progression, documentation of involvement of a specialist gynecologist, reproductive history, menstrual disturbances, menstruation counseling or intervention offered, and diagnosis of early ovarian failure.
RESULTS
Only 16.1% of patients had their menstrual history documented at the initial consult, and 49.6% had their menstrual history documented at a subsequent consult with their treating oncologist or hematologist. Most (82.4%) patients with a menstrual history documented experienced menstrual disturbance posttreatment, most commonly amenorrhea (48.0%), followed by menopause or menopause symptoms (20.6%), irregular menstrual bleeding (16.7%), menorrhagia (13.7%), dysmenorrhea (3.9%), and iron deficiency from bleeding (2.9%). Menopause/Menopausal symptoms and iron deficiency were more likely to be treated than other disturbances.
CONCLUSIONS
Menstruation disturbance is a common side effect of cancer treatment. Menstrual care should be integral to cancer care for people who menstruate, and higher engagement could be achieved through education of medical and allied health staff, information technology systems automating prompts and referral pathways, regular audits to ensure compliance, better alliances between cancer and fertility specialists, and the creation of accessible patient information to promote awareness and facilitate discussion.

Identifiants

pubmed: 37015339
doi: 10.6004/jnccn.2022.7255
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

366-372

Auteurs

Verity Chadwick (V)

Royal North Shore Hospital, St. Leonards, NSW, Australia.

Michaela Kim (M)

University of New South Wales, Kensington, NSW, Australia.

Georgia Mills (G)

Department of Haematology, Kinghorn Cancer Centre, St. Vincent's Hospital, Darlinghurst, NSW, Australia.

Catherine Tang (C)

Department of Haematology and Flow Cytometry, Laverty Pathology, Macquarie Park, NSW, Australia.

Antoinette Anazodo (A)

University of New South Wales, Kensington, NSW, Australia.
Kids Cancer Centre, Sydney Children's Hospital, Randwick, Sydney, NSW, Australia.
Nelune Cancer Centre, Prince of Wales Hospital, Randwick, Sydney, NSW, Australia.

Rachel Dear (R)

University of New South Wales, Kensington, NSW, Australia.
Department of Oncology, St Vincent's Hospital, Darlinghurst, NSW, Australia.

Rachael Rodgers (R)

Department of Reproductive Medicine, Royal Hospital for Women, Randwick, Sydney, NSW, Australia.
School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia.

Orly Lavee (O)

University of New South Wales, Kensington, NSW, Australia.
Department of Haematology, Kinghorn Cancer Centre, St. Vincent's Hospital, Darlinghurst, NSW, Australia.

Samuel Milliken (S)

University of New South Wales, Kensington, NSW, Australia.
Department of Haematology, Kinghorn Cancer Centre, St. Vincent's Hospital, Darlinghurst, NSW, Australia.

Georgia McCaughan (G)

Department of Haematology, Kinghorn Cancer Centre, St. Vincent's Hospital, Darlinghurst, NSW, Australia.

John Moore (J)

University of New South Wales, Kensington, NSW, Australia.
Department of Haematology, Kinghorn Cancer Centre, St. Vincent's Hospital, Darlinghurst, NSW, Australia.

Barbara Withers (B)

University of New South Wales, Kensington, NSW, Australia.
Department of Haematology, Kinghorn Cancer Centre, St. Vincent's Hospital, Darlinghurst, NSW, Australia.

Nada Hamad (N)

Department of Haematology, Kinghorn Cancer Centre, St. Vincent's Hospital, Darlinghurst, NSW, Australia.
St. Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
School of Medicine, University of Notre Dame, Sydney, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH